Root End ResectionNCT07101016
Effect of Local Use of Non-steroidal Anti-inflammatory Agent (Diclofenac Sodium) With and Without Hyaluronidase on Post-surgical Pain and Swelling
A study testing Diclofenac Sodium Gel in people with Root End Resection and Periapical Lesion, run by Mariam Hesham Mahmoud Abdelfattah Eissa.
Trial summary
The goal of this clinical trial is to evaluate whether locally applied diclofenac sodium, with or without hyaluronidase, can reduce post-surgical pain and swelling in adult male and female patients (18 years or older) with asymptomatic single-rooted teeth and periapical lesions (5-10 mm in diameter). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Root End Resection, Periapical Lesion, Single Rooted Teeth
- What is being tested?
- Diclofenac Sodium Gel
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 44 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2025to 8 Aug 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients in good physical health; American Society of Anesthesiologists (ASA) class I or II, with no known allergic manifestations to the drugs used in the study and no involvement with other medication during the study (Appendix 2).
- Patients who are 18 years of age or older, without underlying chronic systemic conditions.
- Male and female patients.
- Patients having asymptomatic single rooted teeth with periapical lesions 5-10mm in diameter (Appendix 3).
- Patients who can understand the visual analogue scale (Appendix 4).
- Patients who accept to participate in the trial and can sign the informed consent (Appendix 1).
Who cannot join
- 1. Teeth with pathosis associated with vertical root fractures, teeth with coronal perforations, and periodontal pockets (7 mm).
- 2. Miller class III/IV mobility, compromised crown-to-root ratio, combined endodontic-periodontic lesions 3. Systemic medical diseases and autoimmune diseases 4. Pregnant females 5. Patients allergic to Diclofenac or Hyaluronidase 6. Teeth with previous root canal therapy
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effect of Local Use of Non-steroidal Anti-inflammatory Agent (Diclofenac Sodium) With and Without Hyaluronidase on Post-surgical Pain and Swelling: A Randomized Clinical Trial
The goal of this clinical trial is to evaluate whether locally applied diclofenac sodium, with or without hyaluronidase, can reduce post-surgical pain and swelling in adult male and female patients (18 years or older) with asymptomatic single-rooted teeth and periapical lesions (5-10 mm in diameter). The main questions it aims to answer are:
Does local application of diclofenac sodium reduce postoperative pain and swelling compared to no medication?
Read more
Does the combination of diclofenac sodium and hyaluronidase offer greater reduction in postoperative pain and swelling than diclofenac sodium alone?
Researchers will compare four groups (diclofenac only, hyaluronidase only, diclofenac + hyaluronidase, and no medicament) to see if the medicated groups experience significantly less pain and swelling after periapical surgery compared to the control group.
Participants will:
Undergo root canal treatment followed by periapical surgery in a single visit.
Receive a randomly assigned intra-osseous gel (diclofenac, hyaluronidase, both, or none) placed into the surgical cavity.
Record their postoperative pain using a visual analogue scale at specified intervals (6, 12, 24, 48 hours, and 7 days).
Return for clinical assessments of swelling at 24, 72 hours, and 5 days post-surgery
Read the detailed description
- Participants, interventions \& outcomes 9. Study settings: The study will be carried out in the endodontic clinic at the faculty of dentistry, Cairo University, Cairo governorate, Egypt.
- The dental Unit is ADEC 200 USA.
- The X-ray machine is FONA XDC, Italy.
- The X-ray sensor plate: Digora intraoral digital sensor plate, Soredex, USA.
- The operator is a PhD student in the department of Endodontics.
- Time: 2025 10. Eligibility criteria:
Inclusion criteria:
- Patients in good physical health; American Society of Anesthesiologists (ASA) class I or II, with no known allergic manifestations to the drugs used in the study and no involvement with other medication during the study (Appendix 2).
- Patients who are 18 years of age or older, without underlying chronic systemic conditions.
- Male and female patients.
- Patients having asymptomatic single rooted teeth with periapical lesions 5-10mm in diameter (Appendix 3).
- Patients who can understand the visual analogue scale (Appendix 4).
- Patients who accept to participate in the trial and can sign the informed consent (Appendix 1).
Exclusion criteria
- Teeth with pathosis associated with vertical root fractures, teeth with coronal perforations, and periodontal pockets (7 mm).
- Miller class III/IV mobility, compromised crown-to-root ratio, combined endodontic-periodontic lesions
- Systemic medical diseases and autoimmune diseases
- Pregnant females
- Patients allergic to Diclofenac or Hyaluronidase
- Teeth with previous root canal therapy
- Interventions Diagnosis The following diagnostic information will be collected to confirm the eligibility of the participants and will be reported in their diagnostic charts (Appendices 2,3)
- Personal data: only patients who are 18 years or older will be included in the trial.
- Medical and dental history: only patients with ASA class I or II will be included in the trial.
- Findings of clinical examination: asymptomatic single rooted teeth, requiring root canal treatment.
- Findings of radiographic examination: patients with periapical radiolucency ranging from 5-10mm in diameter will be included in the trial. After complete diagnosis, healthy adult patients with a periapical radiolucency 5-10mm in diameter related to asymptomatic single rooted teeth, with no known allergic manifestations to the drugs will be included.
Treatment procedure:
All patients will sign an informed consent form after the surgical and experimental procedures are explained verbally and in writing. Patients will be instructed to use Chlorhexidine Gluconate (0.2%) mouthwash, 10 mL twice daily, 3 days preoperatively.
Root canal procedure: local anesthesia will be administered: infiltration injection of 4% articaine with 1:100000 epinephrine.
Access cavity preparation: will be done, under rubber dam isolation, using a round bur and a tapered stone with round end.
Working length determination: will be established using an apex locator and confirmed with a periapical radiograph, ensuring it is 0.5 mm short of the radiographic apex.
Cleaning and shaping: all patients will receive the same hybrid technique treatment, combining coronal and apical preparations. Coronal shaping will be performed using a crown-down approach with rotary nickel-titanium instruments , while apical preparation will be done manually up to size #45 K-file .
Irrigation protocol: during instrumentation, canals will be irrigated with 1 ml of 2.5% sodium hypochlorite between each file, using a 27-gauge slotted, side-vented needle . Apical patency will be maintained using a #10 K-file throughout the procedure. For the final rinse, 5 ml of 2.5% sodium hypochlorite will be followed by 10 ml of distilled water.
Obturation: drying of the canals will be done using paper points matching the final apical file size. A radiograph will be obtained to ensure proper master cone extension (size 45, taper 0.02) The canals will then be obturated with the cold lateral condensation technique using gutta-percha and a resin-based sealer .
Final restoration: the access cavity will be restored with composite resin .
Surgical procedure:
The surgical procedure will follow the root canal treatment in the same visit.
- Chlorhexidine Gluconate 4% scrub, will be applied to the surgical site and the surrounding facial area with sterile gauze and left for 1-2 minutes, then rinsed with sterile saline.
- Supplemental local anesthesia will be administered: infiltration injection of 4% articaine with 1:100000 epinephrine.
- A submarginal incision will be made near the mucogingival junction using a surgical scalpel blade 15c, extending mesially and distally from the treated tooth.
- A full thickness mucoperiosteal flap will be raised with a 9 molt mucoperiosteal elevator. The flap will be mobilized, reflected, and carefully retracted during the root-end management. After flap reflection, a minnesota retractor will be positioned on the exposed cortical bone, with light but firm pressure acting as a passive mechanical barrier to the reflected tissues. The flap will be frequently irrigated with sterile saline to prevent dehydration of the periosteal surface.
- Impact air-handpiece with a tungsten carbide surgical bur will be used for bone cutting.
- Periapical lesions will be removed with sharp bone curettes and angled periodontal curettes. Root apex will be removed 3 mm perpendicular to the long axis of the root apex (apicectomy) at a 90° angle. Ultrasonic tips will be used for root-end preparation and MTA for the root-end filling material.
- The patient will be assigned to either group 1 ,group 2, group 3 or group 4 according to the random sequence for the injected medicament as follows: (1) Diclofenac sodium: 1 mL of gel prepared by incorporating 1 mL of 3 mL/75 mg Voltaren into a 1% Carbopol 940 gel base, will be passively placed in the osseous cavity, (2) Hyaluronidase: 1 mL of gel prepared by dissolving the contents of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and then incorporating 1 mL of this solution into a 1% Carbopol 940 gel base, will be passively placed in the osseous cavity, (3) Diclofenac sodium and Hylauronidase: 1 mL of gel prepared by dissolving the contents of 1 ampoule (1500 IU) Hyalase powder directly in 1 ampoule (3 mL/75 mg) of Voltaren (diclofenac sodium), and then incorporating the entire solution into a Carbopol 940 gel base, will be passively placed in the osseous cavity, (4) The osseous cavity will be irrigated with 5ml of 0.9% sodium chloride, to improve postoperative pain and swelling. All solutions will be injected using a 5ml, 21 gauge needle, syringe.
- All the flaps will be repositioned and sutured with 5-0 nylon non-resorbable interrupted simple sutures, and removed after 7 days.
Soft and hard tissue management will be performed under a surgical microscope (magnification range between 8X and 20X).
Patients will be instructed to continue to use Chlorhexidine Gluconate 0.2% mouthwash, 10 mL twice daily, for an additional 7 days postoperatively beginning 1 day after surgical procedure.
Self-assessment questionnaires will be distributed postoperatively, which will be verbally reviewed by telephone after 6,12, 24, and 48 hours, as well as 7 days after procedure. Patients will also be asked to come back after 24, 72 hours and 5 days to assess the degree of swelling.
Interventions Each osseous cavity will receive 1cc of the injected medication, after root canal preparation, apicectomy, curettage of the lesion and retrofilling with MTA.
Group 1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity Group 2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity Group 3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity Group 4: Suturing of the flap with no medicament
Patients will be given a coded sealed packet preoperatively, that contains 1 of the 4 interventions and the following instructions: (1) No medication; (2) Diclofenac sodium; or (3) Hyaluronidase, or (4) Diclofenac sodium and Hyaluronidase. A dental assistant who is unaware of the experimental protocol will place the coded packets.
- Outcomes: Primary outcome
Postoperative pain intensity measured at 6,12,24, 72 hours and 1 week post-surgical procedure:
Each patient will receive a pain chart containing a 10-cm visual analogue scale (VAS), one for each time interval. The patient will be instructed to rate his/her pain level at the corresponding time interval on a 10-cm visual analogue scale (VAS), scored between 0 (no pain) and 10 (the most unbearable pain). Metin et al. (2018)
Secondary outcome:
Postoperative swelling Each patient will be asked to return for assessment of the swelling, after 24,72 hours and 5 days, which will be conducted by the operator and co-supervisor by comparing the patients initial photograph. The operator and co-supervisor will rate the swelling level at the corresponding time interval as mild (slight puffiness of gum, cheek, or chin but face not distorted), moderate (cheek or chin or both are visibly distorted), and severe (gross distortion of involved part). Morse et al., (1987), Silva et al.(2022)
Tool Unit Time Post-surgical pain Visual analogue scale (VAS) Metin et al. (2018) Categorical 6,12,24,48 hours and 7 days postoperatively Post-surgical swelling Verbal rating scale (VRS) Silva et al.(2022) Categorical 24,72 hours and 5 days postoperatively
- Participant timeline
Before Endodontic and surgical treatment:
- Patients will be carefully diagnosed; clinician will ensure that they met all the eligibility inclusion criteria, and if eligible, they will be treated over a single visit.
- Patients will be instructed on how to use the pain scale chart (VAS)
During Endodontic and surgical treatment:
- Informed consent will be obtained.
- Patients will undergo root canal therapy
- Patients will then be assigned to one of the four groups of the study, according to the random sequence conducted by the assistant supervisor.
- Surgical intervention will be carried out, following instructions of the assigned group.
After Endodontic and surgical treatment:
- Patients will be instructed to record their pain levels every 6, 12, 24, 48 hours and 7 days according to the given instructions. And swelling will be assessed by the operator and co-supervisor every 24,72 hours and 5 days post-surgical treatment
- Another appointment will be scheduled after 7 days to collect the NRS scores and assess the outcome of the treatment and remove the sutures.
- Conditions
- Root End Resection, Periapical Lesion, Single Rooted Teeth
- Being tested
- Diclofenac Sodium Gel
- Keywords
- Periapical lesion, Single rooted teeth, Post operative pain, Post operative swelling, Root end resection, Hyaluronidase, Diclofenac Sodium
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diclofenac Sodium GelDrug
I1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity
| Study group | Role | What they receive |
|---|---|---|
| No medication | No intervention | Osseous cavity left with no medication after root end resection |
| Different types of medications placed in the osseous cavity after root end resection | Experimental | I1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity Receives: Drug: Diclofenac Sodium Gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative pain intensity
Postoperative pain intensity measured at 6,12,24, 72 hours and 1 week post-surgical procedure:
Each patient will receive a pain chart containing a 10-cm visual analogue scale (VAS), one for each time interval. The patient will be instructed to rate his/her pain level at the corresponding time interval on a 10-cm visual analogue scale (VAS), scored between 0 (no pain) and 10 (the most unbearable pain). Metin et al. (2018)
Measured: 6,12,24, 72 hours and 1 week post-surgical procedure
Secondary outcomes (1)
Postoperative swelling
Each patient will be asked to return for assessment of the swelling, after 24,72 hours and 5 days, which will be conducted by the operator and co-supervisor by comparing the patients initial photograph. The operator and co-supervisor will rate the swelling level at the corresponding time interval as mild (slight puffiness of gum, cheek, or chin but face not distorted), moderate (cheek or chin or both are visibly distorted), and severe (gross distortion of involved part). Morse et al., (1987), Silva et al.(2022)
Measured: 24,72 hours and 5 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2025
- Study start1 Aug 2025 (estimated)
- Primary completion1 Aug 2025 (estimated)
- Study completion8 Aug 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Root End ResectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 44 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mariam Hesham Mahmoud Abdelfattah Eissa
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Mariam Hesham Mahmoud Abdelfattah Eissa, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07101016
- Sponsor's protocol ID
- 14422023572518
- Status last verified
- Jul 2025
- First submitted
- 28 Jul 2025
- Last updated
- 3 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Local Use of Non-steroidal Anti-inflammatory Agent (Diclofenac Sodium) With and Without Hyaluronidase on Post-surgical Pain and Swelling: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07101016
- Acronym / sponsor ID
- 14422023572518
- Conditions
- Root End Resection, Periapical Lesion, Single Rooted Teeth
- Keywords
- Periapical lesion, Single rooted teeth, Post operative pain, Post operative swelling, Root end resection, Hyaluronidase, Diclofenac Sodium
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 44 participants (estimated)
- Lead sponsor
- Mariam Hesham Mahmoud Abdelfattah EissaUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 1 Aug 2025 (estimated)
- Study completion
- 8 Aug 2025 (estimated)
- First posted
- 3 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether locally applied diclofenac sodium, with or without hyaluronidase, can reduce post-surgical pain and swelling in adult male and female patients (18 years or older) with asymptomatic single-rooted teeth and periapical lesions (5-10 mm in diameter). The main questions it aims to answer are:
Does local application of diclofenac sodium reduce postoperative pain and swelling compared to no medication?
Does the combination of diclofenac sodium and hyaluronidase offer greater reduction in postoperative pain and swelling than diclofenac sodium alone?
Researchers will compare four groups (diclofenac only, hyaluronidase only, diclofenac + hyaluronidase, and no medicament) to see if the medicated groups experience significantly less pain and swelling after periapical surgery compared to the control group.
Participants will:
Undergo root canal treatment followed by periapical surgery in a single visit.
Receive a randomly assigned intra-osseous gel (diclofenac, hyaluronidase, both, or none) placed into the surgical cavity.
Record their postoperative pain using a visual analogue scale at specified intervals (6, 12, 24, 48 hours, and 7 days).
Return for clinical assessments of swelling at 24, 72 hours, and 5 days post-surgery
Detailed description
- Participants, interventions \& outcomes 9. Study settings: The study will be carried out in the endodontic clinic at the faculty of dentistry, Cairo University, Cairo governorate, Egypt.
- The dental Unit is ADEC 200 USA.
- The X-ray machine is FONA XDC, Italy.
- The X-ray sensor plate: Digora intraoral digital sensor plate, Soredex, USA.
- The operator is a PhD student in the department of Endodontics.
- Time: 2025 10. Eligibility criteria:
Inclusion criteria:
- Patients in good physical health; American Society of Anesthesiologists (ASA) class I or II, with no known allergic manifestations to the drugs used in the study and no involvement with other medication during the study (Appendix 2).
- Patients who are 18 years of age or older, without underlying chronic systemic conditions.
- Male and female patients.
- Patients having asymptomatic single rooted teeth with periapical lesions 5-10mm in diameter (Appendix 3).
- Patients who can understand the visual analogue scale (Appendix 4).
- Patients who accept to participate in the trial and can sign the informed consent (Appendix 1).
Exclusion criteria
- Teeth with pathosis associated with vertical root fractures, teeth with coronal perforations, and periodontal pockets (7 mm).
- Miller class III/IV mobility, compromised crown-to-root ratio, combined endodontic-periodontic lesions
- Systemic medical diseases and autoimmune diseases
- Pregnant females
- Patients allergic to Diclofenac or Hyaluronidase
- Teeth with previous root canal therapy
- Interventions Diagnosis The following diagnostic information will be collected to confirm the eligibility of the participants and will be reported in their diagnostic charts (Appendices 2,3)
- Personal data: only patients who are 18 years or older will be included in the trial.
- Medical and dental history: only patients with ASA class I or II will be included in the trial.
- Findings of clinical examination: asymptomatic single rooted teeth, requiring root canal treatment.
- Findings of radiographic examination: patients with periapical radiolucency ranging from 5-10mm in diameter will be included in the trial. After complete diagnosis, healthy adult patients with a periapical radiolucency 5-10mm in diameter related to asymptomatic single rooted teeth, with no known allergic manifestations to the drugs will be included.
Treatment procedure:
All patients will sign an informed consent form after the surgical and experimental procedures are explained verbally and in writing. Patients will be instructed to use Chlorhexidine Gluconate (0.2%) mouthwash, 10 mL twice daily, 3 days preoperatively.
Root canal procedure: local anesthesia will be administered: infiltration injection of 4% articaine with 1:100000 epinephrine.
Access cavity preparation: will be done, under rubber dam isolation, using a round bur and a tapered stone with round end.
Working length determination: will be established using an apex locator and confirmed with a periapical radiograph, ensuring it is 0.5 mm short of the radiographic apex.
Cleaning and shaping: all patients will receive the same hybrid technique treatment, combining coronal and apical preparations. Coronal shaping will be performed using a crown-down approach with rotary nickel-titanium instruments , while apical preparation will be done manually up to size #45 K-file .
Irrigation protocol: during instrumentation, canals will be irrigated with 1 ml of 2.5% sodium hypochlorite between each file, using a 27-gauge slotted, side-vented needle . Apical patency will be maintained using a #10 K-file throughout the procedure. For the final rinse, 5 ml of 2.5% sodium hypochlorite will be followed by 10 ml of distilled water.
Obturation: drying of the canals will be done using paper points matching the final apical file size. A radiograph will be obtained to ensure proper master cone extension (size 45, taper 0.02) The canals will then be obturated with the cold lateral condensation technique using gutta-percha and a resin-based sealer .
Final restoration: the access cavity will be restored with composite resin .
Surgical procedure:
The surgical procedure will follow the root canal treatment in the same visit.
- Chlorhexidine Gluconate 4% scrub, will be applied to the surgical site and the surrounding facial area with sterile gauze and left for 1-2 minutes, then rinsed with sterile saline.
- Supplemental local anesthesia will be administered: infiltration injection of 4% articaine with 1:100000 epinephrine.
- A submarginal incision will be made near the mucogingival junction using a surgical scalpel blade 15c, extending mesially and distally from the treated tooth.
- A full thickness mucoperiosteal flap will be raised with a 9 molt mucoperiosteal elevator. The flap will be mobilized, reflected, and carefully retracted during the root-end management. After flap reflection, a minnesota retractor will be positioned on the exposed cortical bone, with light but firm pressure acting as a passive mechanical barrier to the reflected tissues. The flap will be frequently irrigated with sterile saline to prevent dehydration of the periosteal surface.
- Impact air-handpiece with a tungsten carbide surgical bur will be used for bone cutting.
- Periapical lesions will be removed with sharp bone curettes and angled periodontal curettes. Root apex will be removed 3 mm perpendicular to the long axis of the root apex (apicectomy) at a 90° angle. Ultrasonic tips will be used for root-end preparation and MTA for the root-end filling material.
- The patient will be assigned to either group 1 ,group 2, group 3 or group 4 according to the random sequence for the injected medicament as follows: (1) Diclofenac sodium: 1 mL of gel prepared by incorporating 1 mL of 3 mL/75 mg Voltaren into a 1% Carbopol 940 gel base, will be passively placed in the osseous cavity, (2) Hyaluronidase: 1 mL of gel prepared by dissolving the contents of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and then incorporating 1 mL of this solution into a 1% Carbopol 940 gel base, will be passively placed in the osseous cavity, (3) Diclofenac sodium and Hylauronidase: 1 mL of gel prepared by dissolving the contents of 1 ampoule (1500 IU) Hyalase powder directly in 1 ampoule (3 mL/75 mg) of Voltaren (diclofenac sodium), and then incorporating the entire solution into a Carbopol 940 gel base, will be passively placed in the osseous cavity, (4) The osseous cavity will be irrigated with 5ml of 0.9% sodium chloride, to improve postoperative pain and swelling. All solutions will be injected using a 5ml, 21 gauge needle, syringe.
- All the flaps will be repositioned and sutured with 5-0 nylon non-resorbable interrupted simple sutures, and removed after 7 days.
Soft and hard tissue management will be performed under a surgical microscope (magnification range between 8X and 20X).
Patients will be instructed to continue to use Chlorhexidine Gluconate 0.2% mouthwash, 10 mL twice daily, for an additional 7 days postoperatively beginning 1 day after surgical procedure.
Self-assessment questionnaires will be distributed postoperatively, which will be verbally reviewed by telephone after 6,12, 24, and 48 hours, as well as 7 days after procedure. Patients will also be asked to come back after 24, 72 hours and 5 days to assess the degree of swelling.
Interventions Each osseous cavity will receive 1cc of the injected medication, after root canal preparation, apicectomy, curettage of the lesion and retrofilling with MTA.
Group 1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity Group 2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity Group 3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity Group 4: Suturing of the flap with no medicament
Patients will be given a coded sealed packet preoperatively, that contains 1 of the 4 interventions and the following instructions: (1) No medication; (2) Diclofenac sodium; or (3) Hyaluronidase, or (4) Diclofenac sodium and Hyaluronidase. A dental assistant who is unaware of the experimental protocol will place the coded packets.
- Outcomes: Primary outcome
Postoperative pain intensity measured at 6,12,24, 72 hours and 1 week post-surgical procedure:
Each patient will receive a pain chart containing a 10-cm visual analogue scale (VAS), one for each time interval. The patient will be instructed to rate his/her pain level at the corresponding time interval on a 10-cm visual analogue scale (VAS), scored between 0 (no pain) and 10 (the most unbearable pain). Metin et al. (2018)
Secondary outcome:
Postoperative swelling Each patient will be asked to return for assessment of the swelling, after 24,72 hours and 5 days, which will be conducted by the operator and co-supervisor by comparing the patients initial photograph. The operator and co-supervisor will rate the swelling level at the corresponding time interval as mild (slight puffiness of gum, cheek, or chin but face not distorted), moderate (cheek or chin or both are visibly distorted), and severe (gross distortion of involved part). Morse et al., (1987), Silva et al.(2022)
Tool Unit Time Post-surgical pain Visual analogue scale (VAS) Metin et al. (2018) Categorical 6,12,24,48 hours and 7 days postoperatively Post-surgical swelling Verbal rating scale (VRS) Silva et al.(2022) Categorical 24,72 hours and 5 days postoperatively
- Participant timeline
Before Endodontic and surgical treatment:
- Patients will be carefully diagnosed; clinician will ensure that they met all the eligibility inclusion criteria, and if eligible, they will be treated over a single visit.
- Patients will be instructed on how to use the pain scale chart (VAS)
During Endodontic and surgical treatment:
- Informed consent will be obtained.
- Patients will undergo root canal therapy
- Patients will then be assigned to one of the four groups of the study, according to the random sequence conducted by the assistant supervisor.
- Surgical intervention will be carried out, following instructions of the assigned group.
After Endodontic and surgical treatment:
- Patients will be instructed to record their pain levels every 6, 12, 24, 48 hours and 7 days according to the given instructions. And swelling will be assessed by the operator and co-supervisor every 24,72 hours and 5 days post-surgical treatment
- Another appointment will be scheduled after 7 days to collect the NRS scores and assess the outcome of the treatment and remove the sutures.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| No medication | No intervention | –Osseous cavity left with no medication after root end resection |
| Different types of medications placed in the osseous cavity after root end resection | Experimental | Drug: Diclofenac Sodium GelI1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients in good physical health; American Society of Anesthesiologists (ASA) class I or II, with no known allergic manifestations to the drugs used in the study and no involvement with other medication during the study (Appendix 2).
- Patients who are 18 years of age or older, without underlying chronic systemic conditions.
- Male and female patients.
- Patients having asymptomatic single rooted teeth with periapical lesions 5-10mm in diameter (Appendix 3).
- Patients who can understand the visual analogue scale (Appendix 4).
Key exclusion criteria (2 listed)
- 1. Teeth with pathosis associated with vertical root fractures, teeth with coronal perforations, and periodontal pockets (7 mm).
- 2. Miller class III/IV mobility, compromised crown-to-root ratio, combined endodontic-periodontic lesions 3. Systemic medical diseases and autoimmune diseases 4. Pregnant females 5. Patients allergic to Diclofenac or Hyaluronidase 6. Teeth with previous root canal therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diclofenac Sodium GelI1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity | Drug | Different types of medications placed in the osseous cavity after root end resection |
Primary outcome
Postoperative pain intensity
Time frame: 6,12,24, 72 hours and 1 week post-surgical procedure
Postoperative pain intensity measured at 6,12,24, 72 hours and 1 week post-surgical procedure: Each patient will receive a pain chart containing a 10-cm visual analogue scale (VAS), one for each time interval. The patient will be instructed to rate his/her pain level at the corresponding time interval on a 10-cm visual analogue scale (VAS), scored between 0 (no pain) and 10 (the most unbearable pain). Metin et al. (2018)
1 secondary outcome
Postoperative swelling
Time frame: 24,72 hours and 5 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Root End Resection
Not yet recruiting
Optimizing Pulp Management in Autotransplantation of Mature Third Molars: A Randomized Controlled Trial
Tooth Avulsion, Dental Pulp Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Diclofenac Sodium Gel in people with Root End Resection and Periapical Lesion, run by Mariam Hesham Mahmoud Abdelfattah Eissa.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mariam Hesham Mahmoud Eissa, MSc (00201001714432, mariam.abdelfattah@dentisrty.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative pain intensity (time frame: 6,12,24, 72 hours and 1 week post-surgical procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2025.